Form 4: Black Diamond Therapeutics Director Shannon Campbell Granted Stock Options
Insider Transaction Report
Black Diamond Therapeutics, Inc. Director Shannon Campbell was granted 30,550 stock options with an exercise price of $2.43, vesting upon specific conditions.
Summary
- Shannon Campbell, a Director of Black Diamond Therapeutics, Inc. (BDTX), was granted 30,550 stock options on June 12, 2025.
- The options have an exercise price of $2.43 per share.
- The options are for Common Stock, totaling 30,550 shares.
- The options will vest in full upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, contingent on Ms. Campbell's continued service.
- The expiration date for these options is June 11, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a routine compensation event, it signifies continued board engagement and alignment of interests, which is generally viewed favorably.
Positives
- The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
- The options have a long expiration date (June 11, 2035), providing ample time for potential value realization.
Future Outlook
The vesting schedule of the stock options indicates an expectation of continued service from Director Shannon Campbell, aligning her incentives with the company's future performance.
Industry Context
The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of non-cash compensation and a mechanism to align management and board interests with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of stock options to a director as part of the company's compensation policy for board members. | 06/12/2025 | Aligns director's long-term interests with shareholder value and incentivizes continued service. |
Related Party Transactions
- The grant of stock options to Director Shannon Campbell constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.
Stakeholder Impact
- Shareholders: The option grant aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
- Employees: No direct impact on general employees from this specific filing.
Next Steps
- The stock options will vest upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 06/12/2025 | Date of stock option grant to Shannon Campbell. |
| 06/12/2026 | Earliest potential vesting date for the stock options, or the Issuer's next annual meeting of stockholders, whichever occurs first. |
| 06/11/2035 | Expiration date of the granted stock options. |
Keywords
Black Diamond Therapeutics, BDTX, Form 4, Stock Option Grant, Insider Transaction, Director Compensation, Shannon Campbell, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.